Search

Objective: Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described., Methods: We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA mutated EOC pts. treated in 15 MITO centers between 1995 and 2017., Results: Three-hundred thirty-one pts. were recorded. Two-hundred forty (72%) and 91 (27.5%) pts. harbored a BRCA1 and BRCA2 mutation, respectively. Median age at diagnosis was 52 years. The most frequent diagnosis was a high grade serous FIGO III or IV EOC and platinum doublet in first-line was administered to almost all pts. Fifty-three % of them had no residual disease (R = 0) at surgery. Median progression-free-survival (mPFS) after first-line chemotherapy was 29 months. Expected percentage of pts. alive at 5 years was 72.5% (CI 60.2-80.8%) and R = 0 predicted a significantly longer overall survival (OS). Sixty-six pts. (19,9%) had both an EOC and a breast cancer (BC) diagnosis. The first diagnosis was BC in 81,8% of cases with a mean interval between the two diagnoses (IBTDs) of 132.4 months. Mutational data show that the founder mutation c.5266dupC in BRCA1 was the most frequently recorded., Conclusions: This is the largest Italian BRCA mutEOC cohort. The only predictor of longer OS was R = 0. EOC pts. that developed subsequently a BC are long-term survivors., Competing Interests: Declaration of Competing Interest Dr. Artioli reports grants from ASTRAZENECA, during the conduct of the study; grants and speaking honoraria from GSK-TESARO, ASTRAZENECA, ROCHE, PHARMAMAR, outside the submitted work; Dr. Giannone reports grants from Roche, outside the submitted work. Dr. Valabrega reports grants and speaking honoraria from Astrazeneca, GSK-Tesaro, Roche, Amgen, and PharmaMar, outside the submitted work. Dr. Pignata was on the Advisory Board for GSK-TESARO, ASTRAZENECA, CLOVIS, ROCHE, PHARMAMAR, MSD, and PFIZER, outside the submitted work;. Dr. Lorusso was on the Advisory Board for Merck AstraZeneca, Roche, Amgen, Clovis, Pharmamar, GSK, Immunogen and Genmab and her Institution received supports from Merck, Clovis, GSK-Tesaro, Dr. De Giorgi reports personal fees and non-financial support from Janssen-Cilag, Astellas, Sanofi, Bayer, Pfizer, BMS, Novartis, Ipsen MSD, Roche, Astrazeneca, Pharmamar, outside the submitted work; Dr. Orditura reports personal fees from GSK-TESARO, outside the submitted work Dr. Borgato reports grants and speaking honoraria from GSK- TESARO, and ASTRAZENECA, outside the submitted work. Dr. Maggiorotto, Dr. Genta, Dr. Cormio, Dr. Scalone, Dr. Nicoletto, Dr. Greco, Dr. Rossi, Dr. Spagnoletti, Dr. Mosconi, Dr. Kardhashi, Dr. Bogliolo, have no conflicts of interest to disclose., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)